Candesartan Cilexetil Tablet
NDC 51407-882
Product Information
Candesartan Cilexetil is a NDA AUTHORIZED GENERIC-approved product labeled by Golden State Medical Supply, Inc.. Candesartan is used to treat high blood pressure (hypertension). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 51407-882 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ACF;004
Code Structure Chart
Product Details
What is NDC 51407-882?
What are the uses of this product?
What are Active Ingredients of this product?
- CANDESARTAN CILEXETIL 4 mg/1 - a prodrug which is metabolized to an active form candesartan to exert its biological effects
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CANDESARTAN CILEXETIL (UNII: R85M2X0D68)
- CANDESARTAN (UNII: S8Q36MD2XX) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- STARCH, CORN (UNII: O8232NY3SJ)
- CARBOXYMETHYLCELLULOSE CALCIUM (UNII: UTY7PDF93L)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 153822 - candesartan cilexetil 4 MG Oral Tablet
- RxCUI: 153823 - candesartan cilexetil 8 MG Oral Tablet
- RxCUI: 577776 - candesartan cilexetil 16 MG Oral Tablet
- RxCUI: 639537 - candesartan cilexetil 32 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.